公开(公告)号：WO2015017328A2

公开(公告)日：2015-02-05

申请号：PCT/US2014/048420

申请日：2014-07-28

申请人： SPALLITTA, Frank Anthony

发明人： SPALLITTA, Frank Anthony

IPC分类号： A01N57/20 ,  A01N57/12 ,  A61K31/662 ,  A61K31/661 ,  A61N5/06

CPC分类号： A01N57/20 ,  A01N57/12 ,  A01N57/14 ,  A01N57/28 ,  A61K9/0075 ,  A61K9/02 ,  A61K9/10 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/661 ,  A61K31/662 ,  A61K31/664 ,  A61K47/36 ,  A61N5/0616

摘要： Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments of the invention are useful for treating skin afflictions including common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis, rosacea and for diagnositic methods thereof.

摘要翻译： 本发明的实施方案涉及通过局部或口服使用有机磷酸盐治疗皮肤疾病。 通过有效地减少或消除受影响的皮肤区域和Demodex螨可能存在的地区的Demodex螨种群，这种处理比任何先前描述的方法都能更好地缓解临床症状和皮肤病症状。 本发明的实施方案可用于治疗皮肤疾病，包括常见的痤疮，脂溢性皮炎，口周皮炎，痤疮性皮炎，短暂性棘皮病，皮肤坏死性坏死性坏死性坏死性坏死性坏死性坏死性坏死性坏死性坏死性皮炎，牛皮癣，类固醇诱发的皮炎，原发性刺激性皮炎，酒渣鼻及其诊断方法。

公开(公告)号：WO2022212399A1

公开(公告)日：2022-10-06

申请号：PCT/US2022/022376

申请日：2022-03-29

申请人： SPALLITTA, Frank Anthony

发明人： SPALLITTA, Frank Anthony

IPC分类号： A01N57/12 ,  A01N57/20 ,  A61K31/661

摘要： Provided herein are methods of treating a clinical symptom and/or transmission risk associated with a pathogen in an individual, including related pharmaceutical formulations, the method comprising the steps of: administering to the individual having the clinical symptom or at transmission risk of the pathogen, an active agent in a dosage effective to inactivate Demodex mites in or on the individual; thereby resulting in amelioration or cessation of the clinical symptoms and/or transmission risk associated with the pathogen.

公开(公告)号：WO2019136211A1

公开(公告)日：2019-07-11

申请号：PCT/US2019/012294

申请日：2019-01-04

申请人： ATTILLAPS HOLDINGS ,  SPALLITTA, Frank Anthony

发明人： SPALLITTA, Frank Anthony

IPC分类号： A01N57/20 ,  A61K31/27

摘要： Provided herein are treatments of autoimmune conditions by the topical, oral or intravenous use of an active agent, including members of the avermectin family, including ivermectin, in an amount effective to reduce or eliminate mites. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the autoimmune afflictions than previously described methods. Methods are useful for treating autoimmune diseases.

公开(公告)号：WO2019136225A1

公开(公告)日：2019-07-11

申请号：PCT/US2019/012315

申请日：2019-01-04

申请人： ATTILLAPS HOLDINGS ,  SPALLITTA, Frank Anthony

发明人： SPALLITTA, Frank Anthony

IPC分类号： A01N33/02 ,  A01N43/34 ,  A61K31/045 ,  A61K31/4706 ,  C07D215/46

摘要： Embodiments of the invention involve treating skin afflictions by the topical or oral use of chloroquine and/or hydroxychloroquines. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. The invention is useful for treating a range of skin afflictions including common acne, atopic dermatitis, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis, rosacea, ocular rosacea/dry eye, and for diagnositic methods thereof.

公开(公告)号：WO2019136221A1

公开(公告)日：2019-07-11

申请号：PCT/US2019/012308

申请日：2019-01-04

申请人： ATTILLAPS HOLDINGS ,  SPALLITTA, Frank Anthony

发明人： SPALLITTA, Frank Anthony

IPC分类号： A01N57/20 ,  A61K31/27

摘要： Provided herein are treatments of autoimmune conditions by the topical, oral or intravenous use of an active agent, specifically including chloroquine and/or hydroxychloroquine, in an amount effective to reduce or eliminate mites. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the autoimmune afflictions than previously described methods. Methods are useful for treating autoimmune diseases.